Sanofi

WBAG:SANO Stock Report

Market Cap: €114.4b

Sanofi Past Earnings Performance

Past criteria checks 0/6

Sanofi's earnings have been declining at an average annual rate of -3.3%, while the Pharmaceuticals industry saw earnings growing at 12.9% annually. Revenues have been growing at an average rate of 6.1% per year. Sanofi's return on equity is 6.2%, and it has net margins of 9.3%.

Key information

-3.3%

Earnings growth rate

-3.2%

EPS growth rate

Pharmaceuticals Industry Growth12.4%
Revenue growth rate6.1%
Return on equity6.2%
Net Margin9.3%
Next Earnings Update30 Jan 2025

Recent past performance updates

Recent updates

Revenue & Expenses Breakdown

How Sanofi makes and spends money. Based on latest reported earnings, on an LTM basis.

Earnings and Revenue History

WBAG:SANO Revenue, expenses and earnings (EUR Millions)
DateRevenueEarningsG+A ExpensesR&D Expenses
30 Sep 2448,4454,50610,9457,147
30 Jun 2447,0804,21610,8426,958
31 Mar 2446,2884,53810,7636,884
31 Dec 2346,0335,40010,7656,728
30 Sep 2345,6999,06610,7036,679
30 Jun 2346,0458,61710,7836,752
31 Mar 2346,1998,35710,7676,780
31 Dec 2245,3898,37110,5396,706
30 Sep 2244,3486,40910,3996,468
30 Jun 2242,0396,64310,0256,176
31 Mar 2240,3426,6669,7845,914
31 Dec 2139,1756,2239,5995,692
30 Sep 2138,4966,1749,4575,622
30 Jun 2137,5465,7779,3625,501
31 Mar 2136,93912,1979,3015,455
31 Dec 2037,36912,2949,4485,530
30 Sep 2037,65011,2249,6135,699
30 Jun 2037,69211,1389,7295,738
31 Mar 2038,2343,4539,9365,973
31 Dec 1937,6312,8559,9676,020
30 Sep 1936,9403,1799,9516,010
30 Jun 1936,7633,5919,9596,111
31 Mar 1936,2644,4399,9985,999
31 Dec 1835,6774,3199,9345,894
30 Sep 1835,3164,0419,9065,680
30 Jun 1834,9853,2439,9185,560
31 Mar 1835,4283,5399,9805,443
31 Dec 1736,2213,77310,1645,472
30 Sep 1736,4004,59310,0775,445
30 Jun 1736,3154,74410,0345,325
31 Mar 1735,6774,6829,8665,246
31 Dec 1634,6964,3959,5925,172
30 Sep 1634,3494,1959,4795,099
30 Jun 1634,1154,1549,4525,191
31 Mar 1634,5694,4409,4585,158
31 Dec 1534,8614,4119,4965,082
30 Sep 1537,2015,29210,1545,195
30 Jun 1532,9104,6288,8734,745
31 Mar 1535,0744,3299,6094,884
31 Dec 1431,9994,2738,5654,667
30 Sep 1433,4844,1128,9454,719
30 Jun 1433,1344,1408,6404,755
31 Mar 1433,0743,8128,6994,752
31 Dec 1331,2913,6398,1074,605

Quality Earnings: SANO has a large one-off loss of €2.0B impacting its last 12 months of financial results to 30th September, 2024.

Growing Profit Margin: SANO's current net profit margins (9.3%) are lower than last year (19.8%).

Free Cash Flow vs Earnings Analysis

Past Earnings Growth Analysis

Earnings Trend: SANO's earnings have declined by 3.3% per year over the past 5 years.

Accelerating Growth: SANO's has had negative earnings growth over the past year, so it can't be compared to its 5-year average.

Earnings vs Industry: SANO had negative earnings growth (-50.3%) over the past year, making it difficult to compare to the Pharmaceuticals industry average (9.5%).

Return on Equity

High ROE: SANO's Return on Equity (6.2%) is considered low.

Return on Assets

Return on Capital Employed

Discover strong past performing companies

7D

1Y

7D

1Y

7D

1Y

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2024/12/20 22:15
End of Day Share Price 2024/12/20 00:00
Earnings2024/09/30
Annual Earnings2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Sanofi is covered by 62 analysts. 16 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Kamla SinghAlphaValue
John EadeArgus Research Company
Odile RundquistBaader Helvea Equity Research